• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pegfilgrastim - Key patent, SPC, and data exclusivity expiry (44 country coverage) Product Image

Pegfilgrastim - Key patent, SPC, and data exclusivity expiry (44 country coverage)

  • Published: September 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Pegfilgrastim
Pegfilgrastim indications: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Pegfilgrastim innovator: Amgen (Neulasta)

Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via READ MORE >

Amgen (Neulasta)

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos